Pegcetacoplan治疗患者的实验室检查发现
本文分析2例阵发性睡眠性血红蛋白尿症和3例C3肾小球病患者接受C3抑制剂pegcetacoplan治疗后的补体实验室变化。C3水平可升至参考上限300%以上,血清蛋白电泳出现额外C3条带,易误判为M蛋白;pegcetacoplan完全阻断旁路途径,经典途径受影响但仍基本完整。
要点
- pegcetacoplan治疗可使C3水平升至参考上限300%以上,非浊度法假象。
- 血清蛋白电泳可出现额外C3条带,不应误判为M蛋白。
- pegcetacoplan完全阻断旁路途径,经典途径受影响但仍基本完整。
核心结论
- pegcetacoplan治疗可导致C3显著升高、血清蛋白电泳出现额外C3条带及旁路途径完全阻断等反直觉实验室改变,临床和实验室人员应知晓。
研究设计与样本
- 对2例PNH和3例C3肾小球病接受pegcetacoplan治疗的患者进行深入补体分析,并结合体外实验和质谱血浆蛋白质组分析。
主要发现
- C3水平升至参考水平以上最高达300%。
- 体外实验表明C3升高并非pegcetacoplan-C3复合物导致的浊度法假象,而可能与C3半衰期延长有关。
- 非靶向质谱血浆蛋白质组分析证实pegcetacoplan诱导循环C3大幅增加。
- 治疗期间观察到properdin(备解素)升高三倍。
- 所有患者血清蛋白电泳出现额外条带,因pegcetacoplan结合的C3质量和电荷改变而不在预期位置迁移,不应误判为M蛋白。
关键数值与推荐
- 体外实验和真实临床实验室结果显示pegcetacoplan完全阻断旁路补体途径,经典途径受影响但仍基本完整。
临床怎么用
- 检验科应识别pegcetacoplan治疗相关的C3升高和血清蛋白电泳额外C3条带,避免误报为M蛋白。
- 解读补体途径活性时应考虑pegcetacoplan对旁路途径的完全阻断作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Complement inhibitor pegcetacoplan binds to C3 and its activation product C3b. Pegcetacoplan has been approved for the treatment of paroxysmal nocturnal hemoglobinuria. Because pegcetacoplan exerts broad inhibition of the complement cascade its efficacy is also investigated in numerous other diseases caused by complement dysregulation, such as C3 glomerulopathy. Pegcetacoplan causes a number of counterintuitive changes in laboratory results. METHODS: In-depth complement analysis in two patients with PNH and three patients with C3 glomerulopathy, all treated with pegcetacoplan. RESULTS: C3 levels increase up to 300 % above reference levels. In vitro testing showed that this is not a turbidimetric artifact in the C3 immunoassay due to pegcetacoplan-C3 complex formation but appears to be caused by increased half-life of C3 bound to pegcetacoplan. Unbiased mass spectrometric plasma proteome analysis confirmed the dramatic pegcetacoplan-induced increase in circulating C3. Surprisingly, also a three-fold increase of properdin was observed during pegcetacoplan treatment. Serum protein electrophoresis showed an additional band in all patients after pegcetacoplan exposure. This C3-band does not migrate at its expected position because of changes in the mass and charge of C3 bound to pegcetacoplan and should therefore not be misinterpreted as an M-protein. Both in vitro experiments and real clinical practice laboratory results demonstrated that pegcetacoplan completely blocked the alternative complement pathway while the classical pathway is affected but remains largely intact. CONCLUSIONS: Because of the increasing use of pegcetacoplan in routine clinical practice, it is important that both clinicians and laboratory specialists are aware of these unexpected therapy-induced laboratory findings.
引用
- Langemeijer SMC, Langereis JD, Avest MT, et al. Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan. Clin Chem Lab Med. 2026. PMID: 41481167. doi:10.1515/cclm-2025-1270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。